Fig. 1From: The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysisKaplan-Meier estimates of overall survival (a) and biochemical progression-free survival (b) in the bicalutamide group and the bicalutamide plus dutasteride groupBack to article page